LSTA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LS

Mkt Cap

$11.2M

Volume

56.77K

Next Earnings

November 5th

Loading chart

LS

LSTALisata Therapeutics, Inc. Common Stock

LSTA

Pay with—

Available Balance0.00

LS

Mkt Cap

$11.6M

Volume

56.77K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their ShareholdersHalper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. Baldwin Group (BWIN) is being sold for $32.50 per share, Lisata Therapeutics (LSTA) for $4.00 per share plus contingent value rights, and ACV for $10.50 per share. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.GlobeNewswire Inc. · Oct 4, 2026

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.Kuva Labs Inc. has commenced a tender offer to acquire Lisata Therapeutics for $4.00 per share in cash plus contingent value rights worth up to $3.00 per share based on achievement of clinical milestones. The transaction values Lisata at a premium to historical market prices and is expected to close in Q3 2026. Lisata's Board unanimously recommends stockholders tender their shares.Benzinga · Jun 10, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA)Law firm Brodsky & Smith has initiated investigations into four merger transactions, examining whether the boards of KalVista Pharmaceuticals, Thermon Group Holdings, Sila Realty Trust, and Lisata Therapeutics breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The deals range in value from approximately $1.9 billion to $2.4 billion.GlobeNewswire Inc. · May 14, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—TALK, LSTA, NSA, and KALVMonteverde & Associates PC is investigating four merger transactions: Talkspace's sale to Universal Health Services at $5.25/share, Lisata Therapeutics' sale to Kuva Labs at $4.00/share plus contingent value rights, National Storage Affiliates Trust's sale to Public Storage at 0.14 shares per unit, and KalVista Pharmaceuticals' sale to Chiesi Group at $27.00/share. The firm is seeking shareholders to determine if the proposed deal terms are fair.GlobeNewswire Inc. · May 12, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - SKYT)Law firm Brodsky & Smith announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Esperion Therapeutics (ARCHIMED acquisition at $3.16/share), Sila Realty Trust (Blue Owl Capital acquisition at $30.38/share), Lisata Therapeutics (Kuva Labs acquisition at $4.00/share plus CVRs), and SkyWater Technology (IonQ acquisition at $35.00/share).GlobeNewswire Inc. · May 5, 2026

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their ShareholdersHalper Sadeh LLC, an investor rights law firm, is investigating Sila Realty Trust's $30.38 per share sale to Blue Owl Real Estate Capital affiliates and Lisata Therapeutics' $4.00 per share sale to Kuva Labs. The firm is examining potential securities law violations and breaches of fiduciary duties, seeking to determine if shareholders are receiving fair consideration and if insider benefits are being prioritized over ordinary shareholder interests.GlobeNewswire Inc. · May 4, 2026

URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LSTA, IBCP, HCBN, and SILAClass action law firm Monteverde & Associates PC announced investigations into several merger and acquisition transactions, including Lisata Therapeutics' sale to Smithfield Foods, Independent Bank Corporation's merger with HCB Financial Corp, and Sila Realty Trust's sale to Sunshine Ultimate Parent LLC. The firm is seeking shareholders who may have concerns about these proposed deals.GlobeNewswire Inc. · May 4, 2026

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.Lisata Therapeutics has agreed to be acquired by privately-held Kuva Labs for $5.00 per share in cash plus a contingent value right of up to $1.00 per share if FDA approval is filed for certepetide within 7 years. The transaction is expected to close in Q2 2026, and Lisata's board unanimously approved the deal. Following completion, Lisata will be delisted from Nasdaq and cease to be a public reporting company.Benzinga · Mar 6, 2026

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.Lisata Therapeutics has agreed to be acquired by privately-held Kuva Labs Inc. for $5.00 per share in cash at closing, plus one contingent value right worth up to $1.00 per share if certepetide receives FDA approval within seven years. The transaction, unanimously approved by Lisata's board, is expected to close in Q2 2026 and will result in Lisata being delisted from Nasdaq.GlobeNewswire Inc. · Mar 6, 2026

Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s InvestigationsInvestor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.GlobeNewswire Inc. · Feb 2, 2026

to start trading

LS

LSTALisata Therapeutics, Inc. Common Stock

LSTA

Pay with—

Available Balance0.00

Your PositionYou don't own any LSTA yet.

Related Tickers

Earnings